Amarin Corporation plc. Analyst Report: Special Situation \ Turnaround Opportunity in Biopharmaceuticals - Targeting large existing cardiovascular health market by BrokerBank Securities, Inc.

NEW YORK, March 28, 2014 /PRNewswire/ -- Amarin Corporation plc AMRN, an established biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health is in the process of attempting a turnaround to return to a growth trajectory.   The Company's lead product, Vascepa (icosapent ethyl) capsules, is approved by the U.S. FDA for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Amarin's lead product is FDA approved and generating revenue in the marketplace.  Initiatives are underway to overcome recent regulatory hurdles and expand approved indications for the drug which could drive accelerated revenues going forward.  GlaxoSmithKline markets a competing and very comparable compound called Lovaza that has validated the available market. Lovaza is estimated to generate about $1 billion in annual sales.  Lovaza has recently come off patent and competition in the segment is likely to pick up meaningfully going forward with substantial market share up for grabs.

An analyst report which details key attributes of the technology, an overview of the company and analyst recommendation can be viewed in its entirety by using the link below. There is no cost, email entry or obligation required to view this report:

http://bit.ly/-AMRN-CFA-Report

copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER 

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein. 

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Andereg, Chartered Financial Analyst. An outsourced research services provider represented by Michael Andereg, Chartered Financial Analyst provided Small Cap Street, LLC this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Small Cap Street, LLC and BrokerBank Securities, Inc. are not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Michael Andereg, Chartered Financial Analyst. 

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@smallcapstreet.com. For any urgent concerns or inquiries, please contact us at admin@smallcapstreet.com.

AMRN has not compensated Small Cap Street, LLC, BrokerBank Securities, Inc., and Michael Andereg, Chartered Financial Analyst for the creation or dissemination of this report. Small Cap Street, LLC, BrokerBank Securities, Inc., and Michael Andereg, Chartered Financial Analyst do not own shares in AMRN. Small Cap Street, LLC and BrokerBank Securities, Inc., is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Small Cap Street, LLC and BrokerBank Securities, Inc. whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC and BrokerBank Securities, Inc. expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC and BrokerBank Securities, Inc. do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

Small Cap Street, LLC is the party responsible for hosting the full analyst report on smallcapstreet.com. BrokerBank Securities in the party responsible for issuing the press release and Michael Andereg, Chartered Financial Analyst is the author of research report.  Information in this release is fact checked and produced on a best efforts basis by Michael Andereg, Chartered Financial Analyst. BrokerBank Securities, Inc. has been compensated one hundred dollars by Small Cap Street, LLC to issue press release. Michael Andereg, Chartered Financial Analyst has been compensated two hundred by Small Cap Street, LLC for the right to disseminate press release and research report. 

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116

SOURCE BrokerBank Securities, Inc.